STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2149 by analyst upside · 2026-06-27
HRMY
Harmony Biosciences Holdings, Inc.
Healthcare · Market Cap $2B · P/E 14.3x
ANALYST PRICE TARGET
+25.1%
implied upside to consensus target
Current Price $35.47
Consensus Target $44.36
Bull Target $85.0
Bear Target $28.0
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
4
Hold
4
Sell
1
52-Week Low $25.52
52-Week High $40.87
YTD Return -5.1%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) 14.3x
Forward P/E 6.4x
EPS (TTM) $2.48
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $899M
Profit Margin 16.2%
52-WEEK RANGE
52-Week Low $25.52
52-Week High $40.87
Current Price $35.47
Bear Target $28.0
Bull Target $85.0
● Now $35.47 ● Target $44.36
TRADING DATA
Avg Volume 805K
YTD Return -5.1%
Analyst Count 11
Consensus Buy
Upside to Target +25.1%
Last Updated 2026-06-27

ANALYST SUMMARY

Harmony Biosciences Holdings, Inc. (HRMY) is currently trading at $35.47 with a Wall Street consensus price target of $44.36, implying potential upside of 25.1% over the next 12 months. 11 analysts currently cover HRMY, with a consensus rating of Buy - 55% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $85.0, while the most cautious has a target of $28.0.

HRMY operates in the Healthcare sector with a market capitalisation of $2B. The stock is down 5.1% year-to-date and is currently trading near the upper end of its 52-week range of $25.52 – $40.87.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for HRMY, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Truist Securities — Reiterated
Hold → Hold 2026-05-08 Building track record
UBS — Reiterated
Neutral → Neutral 2026-02-25 33% win rate (6 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-02-25 31% win rate (48 calls)
B of A Securities — Reiterated
Underperform → Underperform 2026-02-25 Building track record
Needham — Reiterated
Buy → Buy 2026-02-25 20% win rate (5 calls)
UBS ↓ Downgrade
Buy → Neutral 2026-02-11 33% win rate (6 calls)
Truist Securities — Reiterated
Buy → Buy 2026-01-08 Building track record
Mizuho — Reiterated
Outperform → Outperform 2025-12-01 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
26
out of 100
Coverage depth
19/30
Consensus clarity
0/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →